Day: May 7, 2020

SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the BofA Securities Virtual Healthcare Conference 2020. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Tuesday, May 12, 2020 at 3:40 p.m. ET / 12:40 p.m. PT. The virtual conference will be held from May 12-14, 2020.A live audio webcast of the presentation will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available for 30 days following the event.About Kura OncologyKura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise...

BOSTON, May 07, 2020 (GLOBE NEWSWIRE) — resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2020.“Following our extensive review of strategic alternatives, we are pleased about the recently reported merger agreement between resTORbio and Adicet Bio. The combined company will focus on the development of Adicet’s off-the-shelf allogeneic gamma delta T cell therapies for oncology and other indications,” commented Chen Schor, Co-Founder, President and CEO of resTORbio. “We look forward to completing the merger in the second half of 2020 and continuing to work diligently with the Adicet Bio management team...

Option to license an additional five programs for a total of seventeenExtended option and research term to allow for collaboration through 2025Exclusive rights to certain technologies resulting from GTP’s gene therapy researchPHILADELPHIA, May 07, 2020 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders and the Gene Therapy Program (GTP) at the University of Pennsylvania (UPenn) today announced the expansion of their collaboration agreement to include an additional five programs and extending Passage Bio’s period to exercise new programs for an additional three years (through 2025). Additionally, Passage Bio will fund discovery research at GTP and will receive exclusive rights, subject to certain...

– Topline data announcement from the ongoing head-to-head COMPARE trial of SEL-212 remains on schedule for Q3 2020 –– Phase 3 clinical program of SEL-212 to commence in 2H 2020 –– Ongoing COVID-19 pandemic has not materially impacted COMPARE trial progress; continual ongoing assessment and coordination with CRO and clinical sites taking place –– Gene therapy program in collaboration with AskBio remains on track to enter the clinic by Q4 2020 –– Company to host conference call today at 8:30 a.m. ET –WATERTOWN, Mass., May 07, 2020 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today reported financial results for...

NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2020, and provided a corporate update.“In the midst of these unprecedented times we are proud of the agile adaptation of our organization to successfully execute a virtual launch of CAPLYTA, a new treatment option for adult patients suffering from schizophrenia,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “Beyond our commercial efforts, we also continue to make progress in the advancement of our development programs, having completed patient enrollment in our Phase 3 clinical trial evaluating lumateperone as...

On track to submit an IND or IND-equivalent for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020; plans to dose first patient in 2H 2020On track to submit an IND or IND-equivalent for lead TCR-T cell therapy, NTLA-5001 for the treatment of acute myeloid leukemia, in 1H 2021

SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended March 31, 2020 and provided an update on its product pipeline and corporate activities. In lieu of a conference call today, the company plans to host a program update call in June to review the status and timeline to results for the three ongoing clinical trials including the Phase 3 trial of OTIVIDEX® in Ménière’s disease.“As we announced several weeks ago, we have taken steps to ensure the health and safety of our employees, patients, and study site healthcare professionals during the COVID-19 pandemic while also working diligently to mitigate the impact to our ongoing clinical trials,” said David A. Weber,...

Oslo, 7 May 2020: Scatec Solar and partners have grid connected and started commercial operations of the 54 MW Boguslav project in the Kyiv region, Ukraine.“We are pleased to complete our second project in Ukraine less than ten months after closing the financing. The Boguslav solar plant will lead to the abatement of more than 55,000 tonnes of CO² emissions and contribute to growing the share of renewable energy in the country, says Raymond Carlsen, CEO of Scatec Solar.The project is realised under Ukraine’s Feed-in-Tariff scheme and is expected to deliver about 61 GWh per year. The Boguslav plant will be providing clean energy for up to 27,000 households. Public land has been leased for an extended time-period and the solar power plants are expected to deliver power also beyond the Feed-in-tariff period.With this project, Scatec Solar...

Revenues were $2.3 billion in the quarterOperating margin was 9.5%Diluted earnings per share was $4.23Backlog of $45.2 billionReiterates long-term financial targets provided at February 2020 Investor DayNEWPORT NEWS, Va., May 07, 2020 (GLOBE NEWSWIRE) — Huntington Ingalls Industries (NYSE:HII) reported first quarter 2020 revenues of $2.3 billion, up 8.8% from the first quarter of 2019. The increase was driven primarily by higher volume at HII’s Newport News and Ingalls shipbuilding divisions, as well as growth at HII’s Technical Solutions division.Operating income in the quarter was $215 million and operating margin was 9.5%, compared to $161 million and 7.7%, respectively, in the first quarter of 2019. The increases in operating income and operating margin were mainly the result of a more favorable operating FAS/CAS adjustment...